Evaluation of a Novel Manganese-Based Contrast Agent for Cardiac MRI in the Setting of Myocardial Ischemia-Reperfusion
Benjamin Pryor Bonner1,2,3, Jaume Coll-Font1,2,4, Salva Yurista1,2,4, Anna Foster1,2, Robert Eder1,2, Shi Chen1,2, Peter Caravan2,4, Eric Gale2,4, and Christopher Nguyen1,2,4,5
1Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, United States, 2Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, MA, United States, 3Louisiana State University Health Sciences Center, New Orleans, New Orleans, LA, United States, 4Harvard Medical School, Boston, MA, United States, 5Division of Health Science Technology, Harvard-Massachusetts Institute of Technology, Cambridge, MA, United States
Cardiac MRI a powerful imaging modality to assess cardiac anatomy and function, and its utility can be greatly enhanced with the use of contrast agents. Conventional contrast agents are nephrotoxic which limits their utility. We evaluate a novel contrast agent which is safe for use in renal dysfunction. We compare its performance against that of a conventional agent a porcine model of ischemia-reperfusion. This novel contrast agent demonstrates equivalent performance in assessing myocardial fibrotic scars, indicating its potential clinical use in the workout of cardiac patients with renal impairment.
This abstract and the presentation materials are available to members only;
a login is required.